BioWorld

Dec. 23, 2008

Two Aussie Biotechs Merging to Focus on Phase III HIV Dru

Australian biotech firms Progen Pharmaceuticals Ltd. and Avexa Ltd. have agreed to merge, creating a new company with a well-funded oncology and HIV pipeline. (BioWorld Today) Read More

Obama Reveals Top Science Advisers and NOAA Chief

NPS Launches Pivotal Study of NPSP558 in Hypoparathyroidism

Amgen Files BLA for Denosumab in Bone Loss; No Partners (Yet?)

Other News To Note

Appointments And Advancements

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 3, 2026